|
| 37437764 | Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell Transplantation. | Transplant Cell Ther | 2024 |
| 37832948 | Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy. | Annu Rev Pathol | 2024 |
| 38043791 | Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissue: Myeloid Neoplasms. | Mod Pathol | 2024 |
| 36373660 | CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase. | Nucleic Acids Res | 2023 |
| 37808770 | IL-1β-mediated inflammatory signaling drives ineffective erythropoiesis in early-stage myelodysplastic syndromes. | bioRxiv | 2023 |
| 37635400 | Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. | Am J Hematol | 2023 |
| 37485584 | Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. | Am J Hematol | 2023 |
| 38071973 | Genome Mapping Nomenclature. | Cytogenet Genome Res | 2023 |
| 37515433 | Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure. | Am J Hematol | 2023 |
| 37608562 | Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia. | Br J Haematol | 2023 |
| 37821434 | Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma. | Blood Cancer J | 2023 |
| 37532182 | ROS1 Alterations as a Potential Driver of Gliomas in Infant, Pediatric, and Adult Patients. | Mod Pathol | 2023 |
| 35405739 | Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy. | Blood Adv | 2023 |
| 37393344 | Needle in a haystack or elephant in the room? Identifying germline predisposition syndromes in the setting of a new myeloid malignancy diagnosis. | Leukemia | 2023 |
| 36951293 | Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours. | Br J Haematol | 2023 |
| 36951163 | Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). | Haematologica | 2023 |
| 37422688 | A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. | J Hematol Oncol | 2023 |
| 37288826 | Blastoid and Pleomorphic Mantle Cell Lymphoma Demonstrate Distinct Clinicopathologic and Genetic Features. | Am J Surg Pathol | 2023 |
| 37154083 | DDX41 mutations in patients with non-myeloid hematologic neoplasms. | Am J Hematol | 2023 |
| 36990622 | Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study. | Lancet Haematol | 2023 |
| 37185307 | Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations. | Leukemia | 2023 |
| 37183966 | Ultrasensitive NGS MRD assessment in Ph+â¿¿ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1. | Am J Hematol | 2023 |
| 37131217 | Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia. | J Hematol Oncol | 2023 |
| 37196217 | Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in <i>ABL</i> Class Rearrangements. | JCO Precis Oncol | 2023 |
| 36960680 | Myeloid sarcoma with <i>NPM1</i> mutation may be clinically and genetically distinct from AML with <i>NPM1</i> mutation: a study from the Bone Marrow Pathology Group. | Leuk Lymphoma | 2023 |
| 36402146 | Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. | Lancet Haematol | 2023 |
| 36689697 | Clinicopathologic and Molecular Analysis of Normal Karyotype Therapy-Related and De Novo Acute Myeloid Leukemia: A Multi-Institutional Study by the Bone Marrow Pathology Group. | JCO Precis Oncol | 2023 |
| 36683287 | The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors. | Am J Hematol | 2023 |
| 36933995 | Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma. | Pathology | 2023 |
| 36801700 | PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia. | Leuk Res | 2023 |
| 36458426 | A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia. | Cancer | 2023 |
| 36865225 | Targeting DNA2 Overcomes Metabolic Reprogramming in Multiple Myeloma. | bioRxiv | 2023 |
| 36417763 | Optical genome mapping in acute myeloid leukemia: a multicenter evaluation. | Blood Adv | 2023 |
| 36864257 | Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma variant. | Virchows Arch | 2023 |
| 34797699 | Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. | J Clin Oncol | 2022 |
| 35512188 | Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. | Blood | 2022 |
| 35732831 | The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. | Leukemia | 2022 |
| 35704787 | Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. | J Clin Oncol | 2022 |
| 35504958 | Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes. | Mod Pathol | 2022 |
| 35697791 | Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia. | Leukemia | 2022 |
| 35430388 | Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia. | Leuk Res | 2022 |
| 35533262 | High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. | Blood Adv | 2022 |
| 35567779 | TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis. | Am J Hematol | 2022 |
| 35690645 | Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. | Mod Pathol | 2022 |
| 35624339 | A community approach to the cancer-variant-interpretation bottleneck. | Nat Cancer | 2022 |
| 35390143 | TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. | Blood | 2022 |
| 35560245 | Optical genome mapping for structural variation analysis in hematologic malignancies. | Am J Hematol | 2022 |
| 35484266 | Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. | Nat Med | 2022 |
| 35414914 | Consolidative opacity in a patient with acute leukemia. | Clin Case Rep | 2022 |
| 36520477 | Never too old to blame it on your (inherited) genes. | Blood | 2022 |